IP Library Granted Patent US 8,318,708
Granted Patent B2
US 8,318,708 · App. 12/772,981 · Granted Nov 27, 2012

Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis

Assignees: Salk Institute for Biological Studies; University of Sydney
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,708
App. No.
12/772,981
Granted
Nov 27, 2012
Kind
B2
Abstract

This application relates to methods of treating and ameliorating fibrosis, such as fibrosis of the pancreas. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment of pancreatic fibrosis.

Claims (14)

1. A method of treating pancreatic fibrosis in a subject having pancreatic fibrosis, comprising:

administering a therapeutically effective amount of a compound selected from the group consisting of 25-hydroxy-D 3 (25-OH-D 3 ) (calcidiol); vitamin D3 (cholecalciferol); vitamin D2 (ergocalciferol), 1α, 25-dihydroxyvitamin D 3 (calcitriol), calcipotriol, and combinations thereof to a subject having pancreatic fibrosis, thereby treating the fibrosis.

2. The method of claim 1 , wherein administration comprises oral administration of the compound.

3. The method of claim 1 , wherein the compound is administered at a dose of from about 5 international units (IU) to about 50,000 IU.

4. The method of claim 1 , wherein administration comprises contacting pancreatic stellate cells with the compound, thereby treating the fibrosis.

5. The method of claim 1 , wherein the subject is a mammalian subject.

6. The method of claim 1 , wherein the compound is calcipotriol.

7. The method of claim 1 , wherein the compound is 25-hydroxy-D 3 (25-OH-D 3 ) (calcidiol).

8. The method of claim 1 , wherein the compound is vitamin D3 (cholecalciferol).

9. The method of claim 1 , wherein the compound is vitamin D2 (ergocalciferol).

10. The method of claim 1 , wherein the compound is 1α, 25-dihydroxyvitamin D 3 (calcitriol).

11. The method of claim 1 , wherein the subject is a human.

12. A method of treating pancreatic fibrosis in a human subject having pancreatic fibrosis, comprising:

administering a therapeutically effective amount of a calcipotriol to a human subject having pancreatic fibrosis, thereby treating the fibrosis.

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 17, 2015
From: SALK INSTITUTE FOR BIOLOGICAL STUDIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037120/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2010
From: EVANS, RONALD M.; HOWARD HUGHES MEDICAL INSTITUTE
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 025408/0191 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2010
From: DOWNES, MICHAEL
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 025070/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2010
From: LIDDLE, CHRISTOPHER; SUBRAMANIAM, NANTHAKUMAR; SAMER, CAROLINE FLORA
To: UNIVERSITY OF SYDNEY
Reel/Frame 025073/0270 →
Continuity (3)
Continuation In Part 12266513 · Nov 6, 2008
Provisional Application 60985972 · Nov 6, 2007
Related Publication 20110014126A1 · Jan 20, 2011